Transcode Therapeutics (RNAZ) Other Working Capital Changes (2023 - 2025)
Transcode Therapeutics' (RNAZ) quarterly Other Working Capital Changes came in at -$38291.0 in Q1 2025, up 65.55% YoY from -$23128.9 in Q1 2024, and up 66.47% on a QoQ basis from -$114189.0 in Q4 2024.
Transcode Therapeutics (RNAZ) Other Working Capital Changes (2023 - 2025) Analysis & Trends
Transcode Therapeutics (RNAZ) has 3 years of Other Working Capital Changes data on file, last reported at -$38291.0 in Q1 2025.
- Quarterly Other Working Capital Changes rose 65.55% year-over-year to -$38291.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$38291.0 (up 90.71% YoY) and the FY2025 annual result came in at -$38291.0, up 90.71% from the prior year.
- Other Working Capital Changes improved to -$38291.0 in Q1 2025, from -$114189.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $673207.0 in Q1 2023 to a low of -$591460.0 in Q2 2023.
- A 5-year average of -$25787.3 and a median of -$27057.0 in 2024 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes decreased 8.99% — and 2025, when it jumped 65.55%.
- Tracing RNAZ's Other Working Capital Changes over 3 years: stood at -$144123.0 in 2023, then gained by 20.77% to -$114189.0 in 2024, then surged by 66.47% to -$38291.0 in 2025.
- The last three Other Working Capital Changes figures came in at -$38291.0 (Q1 2025), -$114189.0 (Q4 2024), and -$74766.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -38,291.00 |
| Mar 31, 2025 | -38,291.00 |
| Mar 31, 2025 | -38,291.00 |
| Dec 31, 2024 | -114,189.00 |
| Dec 31, 2024 | -114,189.00 |
| Dec 31, 2024 | -114,189.00 |
| Sep 30, 2024 | -74,766.00 |
| Sep 30, 2024 | -74,766.00 |
| Sep 30, 2024 | -74,766.00 |
| Jun 30, 2024 | -112,161.00 |
| Jun 30, 2024 | -112,161.00 |
| Jun 30, 2024 | -112,161.00 |
| Mar 31, 2024 | -111,164.00 |
| Mar 31, 2024 | -111,164.00 |
| Mar 31, 2024 | -111,164.00 |
| Dec 31, 2023 | -144,123.00 |
| Dec 31, 2023 | -144,123.00 |
| Dec 31, 2023 | -144,123.00 |
| Sep 30, 2023 | -68,598.00 |
| Sep 30, 2023 | -68,598.00 |